研究论文
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Antonio Ceriello, Francesco Prattichizzo, Abdul Raouf Mastan Sheik Abdullah, Rosalba La Grotta, Cesare Berra, Barbara McGowan, Alicia Jenkins, Neale Cohen 等 10 位
MultiMedica Istituti di Ricovero e Cura a Carattere Scientifico University of Messina Guy's and St Thomas' NHS Foundation Trust
来源Nature Reviews Endocrinology
年份2026
内容与影响
摘要 · 节选
暂未获取摘要。可打开原文或 PDF，后续可基于全文生成更完整的速读。
逐年被引趋势
320
326
关键指标
3
被引次数 · OpenAlex
20.16
领域内被引倍数
同类平均 = 1
同类平均 = 1
前 0.7%
引用位次
同领域 · 同年份 · 同类型
同领域 · 同年份 · 同类型
149
参考文献
Google Scholar 与 OpenAlex 的被引统计范围不同，数值存在差异属正常。
AI 辅助阅读
依据：文献信息
论文问答
依据：文献信息 · 当前未解析全文
回答优先基于摘要、文献信息与可获取全文；依据不足时会明确说明。
学术脉络
学科主题
生物医学Diabetes Treatment and Management
Bariatric Surgery and Outcomes · Pharmacology and Obesity Treatment
参考文献 149
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
被引 2,637F. Xavier Pi‐Sunyer, Arne Astrup, Ken Fujioka · New England Journal of Medicine · 2015
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
被引 1,150Melanie J. Davies, Richard M. Bergenstal, Bruce W. Bode · JAMA · 2015
Dieting and weight cycling as risk factors for cardiometabolic diseases: who is really at risk?
被引 252J-P Montani, Y. Schütz, Abdul G. Dulloo · Obesity Reviews · 2015
此处列出前 3 条
施引文献 3
Lipid Metabolic Disorders: a Pivotal Driver in Type 2 Diabetes Mellitus Pathogenesis
被引 1Junqi Wu, Huabin Wang, Miao Fu · Current Obesity Reports · 2026
RNA-based approaches in the diagnosis and treatment of obesity
被引 0Karishma Parekh, Gitalee Sarker · Frontiers in Pharmacology · 2026
Psyllium and Glucomannan as Viscous Fiber Modulators of the Gut–Microbiome–Incretin Axis: Molecular Links to Metabolic Inflammation, Barrier Function, and GLP-1 Receptor Agonist Therapy
被引 0Yonghyun Yoon, Jihyo Hwang, C Chia-Kai Yang · International Journal of Molecular Sciences · 2026
按被引量排序，此处列出前 3 条